BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28730856)

  • 1. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
    Chen N; Cui D; Wang Q; Wen Z; Finkelman RD; Welty D
    Xenobiotica; 2018 Jun; 48(6):637-646. PubMed ID: 28730856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
    Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
    Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
    Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of
    Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
    Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction.
    Järvinen E; Hammer HS; Pötz O; Ingelman-Sundberg M; Stage TB
    Clin Pharmacol Ther; 2023 Jun; 113(6):1284-1294. PubMed ID: 36906857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
    Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
    Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
    Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
    Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase.
    Tong Z; Gaudy A; Tatosian D; Ramirez-Valle F; Liu H; Chen J; Hoffmann M; Surapaneni S
    Xenobiotica; 2021 Dec; 51(12):1416-1426. PubMed ID: 35000550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
    Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L
    Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
    Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
    Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
    Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
    Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.
    Sahi J; Sinz MW; Campbell S; Mireles R; Zheng X; Rose KA; Raeissi S; Hashim MF; Ye Y; de Morais SM; Black C; Tugnait M; Keller LH
    Chem Biol Interact; 2006 Feb; 159(2):156-68. PubMed ID: 16356485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.